Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids
Nucleic Acid Therapeutics · 01.08.2024 · 34 (4) · 188-198
DOI: 10.1089/nat.2023.0070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 08.08.2024. Verfasst von Ledong Wan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA. Hauptthemen laut MEDLINE: Organoids, Oligonucleotides, Antisense, Alternative Splicing, Pancreatic Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Aberrant alternative splicing is emerging as a cancer hallmark and a potential therapeutic target. It is the result of dysregulated or mutated splicing factors, or genetic alterations in splicing-regulatory cis -elements. Targeting individual altered splicing events associated with cancer-cell dependencies is a potential therapeutic strategy, but several technical limitations need to be addressed. Patient-derived organoids are a promising platform to recapitulate key aspects of disease states, and to facilitate drug development for precision medicine. Here, we report an efficient antisense-oligonucleotide (ASO) lipofection method to systematically evaluate and screen individual splicing events as therapeutic targets in pancreatic ductal adenocarcinoma organoids. This optimized delivery method allows fast and efficient screening of ASOs, e.g., those that reverse oncogenic alternative splicing. In combination with advances in chemical modifications of oligonucleotides and ASO-delivery strategies, this method has the potential to accelerate the discovery of antitumor ASO drugs that target pathological alternative splicing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.
- Stony Brook University, Stony Brook, New York, USA.
- Department of Biochemistry, University of Colorado, Boulder, Colorado, USA.
ORCID-Profile: Adrian R Krainer
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Wan, L., Kral, A. J., Voss, D., Schäfer, B., Sudheendran, K., Danielsen, M., Caruthers, M. H., & Krainer, A. R. (2024). Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. Nucleic Acid Therapeutics, 34(4), 188-198. https://doi.org/10.1089/nat.2023.0070
Vancouver
Wan L, Kral AJ, Voss D, Schäfer B, Sudheendran K, Danielsen M, et al. Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. Nucleic Acid Therapeutics. 2024;34(4):188-198. doi:10.1089/nat.2023.0070
BibTeX
@article{Wan2024,
author = {Wan, Ledong and Kral, Alexander J and Voss, Dillon and Schäfer, Balázs and Sudheendran, Kavitha and Danielsen, Mathias and Caruthers, Marvin H and Krainer, Adrian R},
title = {Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids},
journal = {Nucleic Acid Therapeutics},
year = {2024},
volume = {34},
number = {4},
pages = {188--198},
doi = {10.1089/nat.2023.0070}
}
EUVIMED